Diagnostic strategies for early recognition of cancer therapeutics–related cardiac dysfunction

Carlos R. Manrique, Michael Park, Nidhish Tiwari, Juan Carlos Plana, Mario J. Garcia

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics–related cardiovascular dysfunction (CTRCD). This review article will focus on the early diagnosis of left ventricular dysfunction associated with chemotherapy. Currently, the identification of cardiac toxicity associated with cancer treatment is the cornerstone for critical decisions regarding anticancer therapy and cardioprotective strategies. Its early detection, especially in subclinical phases, allows immediate intervention to prevent further impairment of the myocardium and other cardiovascular structures. The most significant published studies were selected for this revision, providing an updated document for the health professionals involved in the care of patients with cancer. We examined the current evidence and recommendations for biochemical and noninvasive diagnostic techniques, including their specific role for identification of CTRCD. Traditional and advanced imaging modalities, used alone or in combination with cardiovascular biomarkers, are essential for the recognition of cardiotoxicity during cancer therapy. Evolving basic and clinical research are focused on the development of more sensitive and specific diagnostic tools and for the recognition of cardiac toxicity.

Original languageEnglish (US)
JournalClinical Medicine Insights: Cardiology
Volume11
DOIs
StatePublished - Jan 1 2017

Fingerprint

Heart Neoplasms
Neoplasms
Second Primary Neoplasms
Left Ventricular Dysfunction
Cardiovascular System
Cardiology
Research
Antineoplastic Agents
Survivors
Early Diagnosis
Myocardium
Patient Care
Cardiovascular Diseases
Therapeutics
Biomarkers
Quality of Life
Drug Therapy
Survival
Incidence
Health

Keywords

  • Cardiomyopathy
  • Cardiotoxicity
  • Chemotherapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diagnostic strategies for early recognition of cancer therapeutics–related cardiac dysfunction. / Manrique, Carlos R.; Park, Michael; Tiwari, Nidhish; Plana, Juan Carlos; Garcia, Mario J.

In: Clinical Medicine Insights: Cardiology, Vol. 11, 01.01.2017.

Research output: Contribution to journalReview article

@article{ec5a4d3c5d7b45d6a47bc885d950b9f9,
title = "Diagnostic strategies for early recognition of cancer therapeutics–related cardiac dysfunction",
abstract = "Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics–related cardiovascular dysfunction (CTRCD). This review article will focus on the early diagnosis of left ventricular dysfunction associated with chemotherapy. Currently, the identification of cardiac toxicity associated with cancer treatment is the cornerstone for critical decisions regarding anticancer therapy and cardioprotective strategies. Its early detection, especially in subclinical phases, allows immediate intervention to prevent further impairment of the myocardium and other cardiovascular structures. The most significant published studies were selected for this revision, providing an updated document for the health professionals involved in the care of patients with cancer. We examined the current evidence and recommendations for biochemical and noninvasive diagnostic techniques, including their specific role for identification of CTRCD. Traditional and advanced imaging modalities, used alone or in combination with cardiovascular biomarkers, are essential for the recognition of cardiotoxicity during cancer therapy. Evolving basic and clinical research are focused on the development of more sensitive and specific diagnostic tools and for the recognition of cardiac toxicity.",
keywords = "Cardiomyopathy, Cardiotoxicity, Chemotherapy",
author = "Manrique, {Carlos R.} and Michael Park and Nidhish Tiwari and Plana, {Juan Carlos} and Garcia, {Mario J.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1179546817697983",
language = "English (US)",
volume = "11",
journal = "Clinical Medicine Insights: Cardiology",
issn = "1179-5468",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Diagnostic strategies for early recognition of cancer therapeutics–related cardiac dysfunction

AU - Manrique, Carlos R.

AU - Park, Michael

AU - Tiwari, Nidhish

AU - Plana, Juan Carlos

AU - Garcia, Mario J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics–related cardiovascular dysfunction (CTRCD). This review article will focus on the early diagnosis of left ventricular dysfunction associated with chemotherapy. Currently, the identification of cardiac toxicity associated with cancer treatment is the cornerstone for critical decisions regarding anticancer therapy and cardioprotective strategies. Its early detection, especially in subclinical phases, allows immediate intervention to prevent further impairment of the myocardium and other cardiovascular structures. The most significant published studies were selected for this revision, providing an updated document for the health professionals involved in the care of patients with cancer. We examined the current evidence and recommendations for biochemical and noninvasive diagnostic techniques, including their specific role for identification of CTRCD. Traditional and advanced imaging modalities, used alone or in combination with cardiovascular biomarkers, are essential for the recognition of cardiotoxicity during cancer therapy. Evolving basic and clinical research are focused on the development of more sensitive and specific diagnostic tools and for the recognition of cardiac toxicity.

AB - Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field. Multidisciplinary efforts have been focused on the prevention, diagnosis, and treatment of cancer therapeutics–related cardiovascular dysfunction (CTRCD). This review article will focus on the early diagnosis of left ventricular dysfunction associated with chemotherapy. Currently, the identification of cardiac toxicity associated with cancer treatment is the cornerstone for critical decisions regarding anticancer therapy and cardioprotective strategies. Its early detection, especially in subclinical phases, allows immediate intervention to prevent further impairment of the myocardium and other cardiovascular structures. The most significant published studies were selected for this revision, providing an updated document for the health professionals involved in the care of patients with cancer. We examined the current evidence and recommendations for biochemical and noninvasive diagnostic techniques, including their specific role for identification of CTRCD. Traditional and advanced imaging modalities, used alone or in combination with cardiovascular biomarkers, are essential for the recognition of cardiotoxicity during cancer therapy. Evolving basic and clinical research are focused on the development of more sensitive and specific diagnostic tools and for the recognition of cardiac toxicity.

KW - Cardiomyopathy

KW - Cardiotoxicity

KW - Chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85034665820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034665820&partnerID=8YFLogxK

U2 - 10.1177/1179546817697983

DO - 10.1177/1179546817697983

M3 - Review article

VL - 11

JO - Clinical Medicine Insights: Cardiology

JF - Clinical Medicine Insights: Cardiology

SN - 1179-5468

ER -